Determination of EEG Microstates Associated With Mental Disorders in At-Risk States (Détermination Des Microétats EEG associés Aux Troubles Psychiques Dans Les États à Risque - DEMETER)

Status: Recruiting
Location: See location...
Intervention Type: Device, Biological, Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this observational study is to compare subjects with at-risk-mental-state, early psychosis, schizophrenia, depression, and autism spectrum disorders, with healthy controls (N = 21 x 6). The main questions it aims to answer are: * are EEG microstate anomalies associated with diagnosis, clinical and functional prognosis, both in resting conditions and during sleep ? * are EEG microstates anomalies associated with differences in sensorimotor integration, prosodic and conversational, interoceptive, and narrative self ? * an ancillary study will be to see whether in healthy controls EEG microstate properties vary under light hypnosis conditions. Participants will: * undergo deep phenotyping based on psychopathology and neuropsychological assessments * undergo a high-resolution EEG (64 electrodes) with a resting period and a sensorimotor task; and healthy controls will have a light hypnosis period. * undergo a recording of the characteristics of their voice (tone, prosody) * undergo a one-night polysomnography * undergo MRI and biological sampling for multi-omic analyses * undergo a virtual reality experience

Eligibility
Participation Requirements
Sex: All
Minimum Age: 15
Maximum Age: 30
Healthy Volunteers: t
View:

• age between 15 and 30 years

• subjects meeting CAARMS criteria for stage Ia or Ib mental states at risk (for stage Ia, mild or nonspecific symptoms of psychosis or severe mood disorder, and mild functional impairment; for stage Ib, moderate symptoms below intervention threshold and moderate functional impairment)

• subjects meeting any DSM-5 criteria associated with a first onset of psychotic symptoms (first episode psychosis)

• subjects satisfying DSM-5 criteria for depressive disorder

• subjects meeting DSM-5 criteria for autism spectrum disorder

• healthy control subjects recruited from the general population

Locations
Other Locations
France
Centre de Recherche Clinique, Hôpital Sainte-Anne, GHU Paris Psychiatrie et Neurosciences
RECRUITING
Paris
Contact Information
Primary
Anton Iftimovici, MD, PhD
anton.iftimovici@ghu-paris.fr
0033(0)145658179
Backup
Valeria Lucarini, MD, MS
valeria.lucarini@ghu-paris.fr
0033(0)145658179
Time Frame
Start Date: 2023-05-30
Estimated Completion Date: 2026-07-30
Participants
Target number of participants: 126
Treatments
Experimental: Major depressive disorder
Major depressive disorder as defined by DSM-5 classification
Experimental: Autism spectrum disorder
Autism spectrum disorder as defined by DSM-5 classification
Experimental: At risk mental state
At risk mental state as defined in the CAARMS
Experimental: First episode psychosis
Any DSM-5 category associated with psychotic symptoms
Experimental: Schizophrenia
Schizophrenia as defined by DSM-5 classification
Experimental: Healthy controls
Healthy controls with no history of neurodevelopmental disorder or psychotic disorder in a first degree relative
Related Therapeutic Areas
Sponsors
Leads: Centre Hospitalier St Anne
Collaborators: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov